Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of TACE + radiotherapy + camrelizumab + apatinib for hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR2200058539Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200058539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058539.